EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q3 2025 Earnings Call Transcript
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q3 2025 Earnings Call Transcript November 5, 2025EyePoint Pharmaceuticals, Inc. misses on earnings expectations.
Eyepoint Pharmaceuticals Inc. (EYPT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Cormorant Asset Management Bihua Chen | 8,325,000 | $118,548,000 | 8.18% | |
| 2. | Suvretta Capital Management Aaron Cowen | 6,192,715 | $88,184,262 | -9% | 2.26% |
| 3. | Adage Capital Management Phill Gross And Robert Atchinson | 5,559,782 | $79,171,296 | -19% | 0.13% |
| 4. | Citadel Investment Group Ken Griffin | 2,135,389 | $30,407,939 | -9% | 0% |
| 5. | OrbiMed Advisors Samuel Isaly | 1,796,000 | $25,575,040 | 0.6% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.99 | 5,000 | $29,950.00 | 36,500 | 2025-05-19 | Filing | |
| $5.81 | 5,000 | $29,050.00 | 31,500 | 2025-05-16 | Filing | |
| $5.47 | 5,000 | $27,350.00 | 26,500 | 2025-05-15 | Filing | |
| $5.42 | 5,000 | $27,100.00 | 21,500 | 2025-05-14 | Filing | |
| $7.79 | 2,567 | $19,996.93 | 9,967 | 2024-08-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.61 | 2,722 | $31,602.42 | 0 | 2025-11-11 | Filing | |
| $10.06 | 11,625 | $116,995.16 | 1,850 | 2024-07-12 | Filing | |
| $10.30 | 11,625 | $119,704.95 | 3,700 | 2024-06-03 | Filing | |
| $12.65 | 11,625 | $147,044.63 | 5,550 | 2024-05-14 | Filing | |
| $28.49 | 209 | $5,954.41 | 37,962 | 2024-02-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,964,526 | $70,694,849 | 0% | |
| 2. | 4,416,332 | $62,888,567 | 0.11% | |
| 3. | 4,171,884 | $59,407,621 | 0.01% | |
| 4. | 3,794,516 | $54,033,908 | 0% | |
| 5. | 3,572,335 | $50,870,050 | 2.5% |
News See All
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q2 2025 Earnings Call Transcript
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q2 2025 Earnings Call Transcript August 6, 2025EyePoint Pharmaceuticals, Inc. misses on earnings expectations.
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2025 Earnings Call Transcript
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2025 Earnings Call Transcript May 7, 2025EyePoint Pharmaceuticals, Inc. reports earnings inline with expectations.
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2024 Earnings Call Transcript
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2024 Earnings Call Transcript March 5, 2025EyePoint Pharmaceuticals, Inc. misses on earnings expectations.
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript
Operator: Good morning. My name is Kevin and I will be your conference operator today.
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q3 2023 Earnings Call Transcript
Operator: Good morning. My name is Leeway and I will be your conference operator today.
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q2 2023 Earnings Call Transcript
Operator: Good morning. My name is [indiscernible] and I will be your conference operator today.
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2023 Earnings Call Transcript
Operator: Good morning. My name is Desean, and I will be your conference operator today.
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2022 Earnings Call Transcript
Operator: Good day and welcome to the EyePoint Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Were Hedge Funds Right About EyePoint Pharmaceuticals, Inc. (EYPT)?
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).